Nuvation Bio (NUVB) versus Its Rivals Critical Comparison

Nuvation Bio (NYSE:NUVB) is one of 844 public companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare Nuvation Bio to related businesses based on the strength of its analyst recommendations, profitability, valuation, risk, institutional ownership, earnings and dividends.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Nuvation Bio and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvation Bio	1	2	9	0	2.67
Nuvation Bio Competitors	9828	15119	45430	1586	2.54

Nuvation Bio currently has a consensus price target of $12.89, suggesting a potential upside of 209.83%. As a group, “Biotechnology” companies have a potential upside of 102.59%. Given Nuvation Bio’s stronger consensus rating and higher possible upside, analysts plainly believe Nuvation Bio is more favorable than its rivals.

Volatility & Risk

Nuvation Bio has a beta of 1.73, meaning that its share price is 73% more volatile than the S&P 500. Comparatively, Nuvation Bio’s rivals have a beta of 1.12, meaning that their average share price is 12% more volatile than the S&P 500.

Earnings & Valuation

This table compares Nuvation Bio and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Nuvation Bio	$62.90 million	-$204.63 million	-10.40
Nuvation Bio Competitors	$691.14 million	$10.43 million	-15.00

Nuvation Bio’s rivals have higher revenue and earnings than Nuvation Bio. Nuvation Bio is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Nuvation Bio and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nuvation Bio	-88.18%	-46.59%	-22.01%
Nuvation Bio Competitors	-9,046.59%	-199.78%	-30.61%

Insider and Institutional Ownership

61.7% of Nuvation Bio shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 30.1% of Nuvation Bio shares are held by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Nuvation Bio beats its rivals on 10 of the 13 factors compared.

Nuvation Bio Company Profile

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.